Adalimumab-induced lupus in a patient with hidradenitis suppurativa

Authors

Dilara TurkFollow
Gautham Vellaichamy
Alexis Lyons, Henry Ford Health System
Angela Parks-Miller, Henry Ford Health System
Tamara Nelson
Alireza Meysami, Henry Ford Health System
Iltefat Hamzavi, Henry Ford Health SystemFollow

Files

Program

WSU Medical School

Training Level

Medical Student

Institution

Wayne State University

Abstract

Anti-tumor necrosis factor (TNF) agents are used to treat various inflammatory disorders, such as rheumatoid arthritis, irritable bowel disease, and hidradenitis suppurativa (HS). A known side effect of these agents is the development of autoimmunity with the formation of antinuclear antibodies and/or anti-dsDNA antibodies. Although patients sometimes develop these antibodies, they rarely exhibit clinical manifestations. If symptoms do develop, the diagnosis of anti-TNF induced lupus (ATIL) should be considered. We describe a case of adalimumab-induced lupus in a patient with hidradenitis suppurativa.

Presentation Date

5-2019

Recommended Citation

Turk, Dilara; Vellaichamy, Gautham; Lyons, Alexis; Parks-Miller, Angela; Nelson, Tamara; Meysami, Alireza; and Hamzavi, Iltefat, "Adalimumab-induced lupus in a patient with hidradenitis suppurativa" (2019). Case Reports. 113.
https://scholarlycommons.henryford.com/merf2019caserpt/113